Post-Stent Dual Antiplatelet Therapy Protocol
After coronary stent placement, administer aspirin 162-325 mg daily initially, then transition to 75-162 mg daily long-term indefinitely, combined with clopidogrel 75 mg daily for at least 12 months after drug-eluting stent (DES) placement or minimum 1 month (ideally up to 12 months) after bare-metal stent (BMS) placement. 1, 2
Initial Aspirin Dosing
Higher-dose aspirin (162-325 mg daily) should be given for:
- 1 month after BMS implantation
- 3 months after sirolimus-eluting stent implantation
- 6 months after paclitaxel-eluting stent implantation
After these initial periods, transition to maintenance aspirin 75-162 mg daily indefinitely 1, 2
Bleeding Risk Consideration
For patients with bleeding concerns, lower-dose aspirin (75-162 mg daily) is reasonable even during the initial post-stent period 2. The evidence shows no significant trials comparing lower-dose (75-100 mg) versus higher-dose (162-325 mg) aspirin for stent thrombosis prevention, but two major trials demonstrated increased bleeding risk with higher-dose aspirin 2.
Clopidogrel Duration
Drug-Eluting Stents (DES):
- Minimum 12 months of clopidogrel 75 mg daily if not at high bleeding risk 2
- Continuation beyond 12 months may be considered (Class IIb recommendation) 2, 1
Bare-Metal Stents (BMS):
- Minimum 1 month of clopidogrel 75 mg daily
- If increased bleeding risk: minimum 2 weeks 2
- Ideally extend to 12 months in all patients not at high bleeding risk 2
Loading Dose Protocol
Clopidogrel loading dose of 600 mg should be administered before or when PCI is performed 2. The guidelines note that while 300 mg has established efficacy when given at least 6 hours before the procedure, 600 mg achieves more rapid platelet inhibition 2.
Exception: In patients undergoing PCI within 12-24 hours of fibrinolytic therapy, a 300 mg loading dose may be considered 2.
Critical Warnings
Premature Discontinuation
Early discontinuation of clopidogrel is the major predictor of stent thrombosis (hazard ratio 13.74) 3. Stent thrombosis, though occurring in only ~1% of patients, presents as acute coronary syndrome with mortality rates up to 45% 4.
High-Risk Features for Late Stent Thrombosis
Predictors include: small vessels, multiple lesions, long stents, overlapping stents, ostial or bifurcation lesions, prior brachytherapy, suboptimal stent result, low ejection fraction, advanced age, diabetes, renal failure, acute coronary syndrome, and premature antiplatelet discontinuation 2.
Patients should be counseled on the need for and risks of dual antiplatelet therapy before stent placement, and elective surgery should be postponed during the mandatory treatment period 2.
Special Populations
Acute Coronary Syndrome (ACS): For patients with ACS (STEMI or NSTEMI) undergoing PCI, clopidogrel 75 mg daily should be given for at least 12 months 5, 6. Consider ticagrelor or prasugrel as alternatives to clopidogrel in this population 5.
Warfarin Co-administration: If warfarin is required (e.g., atrial fibrillation), use INR target 2.0-2.5 with low-dose aspirin (75-81 mg) and clopidogrel 75 mg, recognizing this significantly increases bleeding risk and requires close monitoring 1.
Maintenance Phase Beyond Initial Period
After completing the initial intensive period, continue aspirin 75-162 mg daily indefinitely 1, 2, 7. The combination of aspirin and clopidogrel beyond 12 months reduces cardiovascular ischemic events but must be balanced against bleeding risk 2.